Navigation Links
New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
Date:10/16/2007

NUTLEY, N.J., Oct. 17 /PRNewswire/ -- Ten abstracts providing new analyses of data from six major Phase III renal anemia studies for MIRCERA(R) will be presented at the upcoming 40th Annual Meeting of the American Society of Nephrology (ASN) in San Francisco on November 2 - 5, 2007.

Among the highlights will be new analyses from maintenance studies, including MAXIMA, PROTOS, STRIATA and RUBRA, and correction studies, including ARCTOS and AMICUS.

Please note all information presented at the ASN annual meeting is embargoed for media release until one hour after the time of presentation.

Abstracts accepted for the ASN annual meeting include:

-- Once-monthly intravenous (IV) C.E.R.A. maintains stable hemoglobin (Hb)

in dialysis patients (pts), irrespective of age or gender. S. Fishbane

et al. (SU-PO779. November 4: 10:00 a.m. - 12:00 p.m. PST. Exhibit

Hall, Moscone Center)

-- Stable hemoglobin (Hb) levels are maintained with once-monthly C.E.R.A.

in dialysis patients (pts), irrespective of mode of vascular access. F.

Locatelli et al. (SU-PO822. November 4: 10:00 a.m. - 12:00 p.m. PST.

Exhibit Hall, Moscone Center)

-- Once-monthly C.E.R.A. maintains stable hemoglobin (Hb) in patients

(pts) with chronic kidney disease (CKD), irrespective of baseline iron

levels. A. Nissenson et al. (SU-PO819. November 4: 10:00 a.m. - 12:00

p.m. PST. Exhibit Hall, Moscone Center)

-- C.E.R.A. maintains stable hemoglobin (Hb) in chronic kidney disease

(CKD), regardless of albumin or dialysis adequacy (Kt/V). W. Sulowicz

et al. (Publication Only)

-- Effect of baseline hemoglobin (Hb) on Hb stability in patients (pts)

with chronic kidney disease (CKD) receiving once-monthly C.E.R.A. N.W.

Levin et al. (SU-PO817. November 4: 10:00 a.m. - 12:00 p.m. PST.

Exhibit Hall, Moscone Center)

-- Anemia correction with C.E.R.A. in patients (pts) with chronic kidney

disease (CKD) is unaffected by baseline hemoglobin (Hb) level. R.

Provenzano et al. (SU-PO796. November 4: 10:00 a.m. - 12:00 p.m. PST.

Exhibit Hall, Moscone Center)

-- Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is

similar to that with other erythropoiesis stimulating agents (ESAs). P.

Barany et al. (SU-PO795. November 4: 10:00 a.m. - 12:00 p.m. PST.

Exhibit Hall, Moscone Center)

-- Diabetes status and ethnicity do not alter efficacy of C.E.R.A. in

patients with chronic kidney disease: analysis of 3 phase III trials.

T. Golper et al. (SU-PO1019. November 4: 10:00 a.m. - 12:00 p.m. PST.

Exhibit Hall, Moscone Center)

-- C.E.R.A. maintains hemoglobin in dialysis patients directly switched

from epoetin (EPO) without increasing iron therapy requirements. A.

Nissenson et al. (F-PO855. November 2: 10:00 a.m. - 12:00 p.m. PDT.

Exhibit Hall, Moscone Center)

-- C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD

patients on dialysis with and without congestive heart failure: pooled

Phase III analysis. S. Fishbane et al. (F-PO843. November 2:

10:00 a.m. - 12:00 p.m. PDT. Exhibit Hall, Moscone Center)

About MIRCERA

The clinical program for MIRCERA consisted of 10 global studies involving more than 2,700 patients from 29 countries. The Phase III program for MIRCERA included two correction studies and four maintenance studies exploring intravenous (IV) and subcutaneous (SC) MIRCERA at extended administration intervals.

MIRCERA has a longer half-life than any commercially available erythropoiesis-stimulating agent (ESA). In clinical trials MIRCERA corrected anemia in chronic kidney disease (CKD) patients with dosing once every two weeks and maintained hemoglobin levels in CKD patients with dosing intervals up to once monthly. In the U.S., the FDA is completing its review and MIRCERA is anticipated to be approved mid-November.

Safety Information

MIRCERA has a demonstrated safety profile comparable to other erythropoietic agents.

The most commonly reported adverse events in the MIRCERA Phase II/III clinical program were hypertension, nasopharyngitis, diarrhea, headache, and upper respiratory tract infection.

Erythropoietic therapies increase the risk of death and serious cardiovascular and thromboembolic events when administered to a hemoglobin of greater than 12 g/dL. A rate of Hb rise of >1 g/dL over 2 weeks may also contribute to these risks.

Erythropoiesis stimulating agents, when administered to target a hemoglobin of greater than 12 g/dL, have shortened the time to tumor progression, shortened survival and increased the risk of death in cancer patients.

Pure Red Cell Aplasia (PRCA) has been observed in patients treated with erythropoietin therapy. However, PRCA has not been observed with MIRCERA in clinical trials to date.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and quality of life. An employer of choice, in 2007 Roche was named Top Company of the Year by Med Ad News and one of the Top 20 Employers (Science magazine). In 2006, Roche was ranked the No. 1 Company to Sell For (Selling Power), and one of AARP's Top Companies for Older Workers, and in 2005, Roche was named one of Fortune magazine's Best Companies to Work For in America. For additional information about the U.S. pharmaceuticals business, visit our websites: http://www.rocheusa.com or http://www.roche.us.

All trademarks used or mentioned in this release are protected by law.


'/>"/>
SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Data Analyses Outline Efficacy and Safety of Mircera for the Treatment of Renal Anemia Associated With Chronic Kidney Disease
5. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
6. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
7. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
8. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
9. AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical Pipeline to Be Featured at AACR
10. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
11. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... VIEW, Calif. , Feb. 10, 2016 ... of a synergistic confluence of various technologies ... value propositions, previously unavailable. These opportunities create ... and convergence, in turn, drives the development ... entrepreneurial scenario is characterized by technology convergences, ...
(Date:2/10/2016)... , Feb. 10, 2016 /PRNewswire/ - The President of ... announced the release of an anti-radiation product from ... revolutionary breakthrough in the treatment of cancer using ... It will assist in the healing of radiation ... will also protect only the healthy cells from ...
(Date:2/10/2016)... , Feb. 10, 2016 Intouch ... recently identified an industry-wide trend regarding the evolution ... allows organizations to efficiently deliver compelling sales presentations ... 2011 and another in 2015, Intouch uncovered that ... tablet devices and DSAs, many are not using ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Early this week, Team Iconic at ... of Nestlé KITKAT as the first global confectionery brand sourced from 100% sustainable cocoa. ... the quality of their product, through activities that focus on better farming, better lives ...
(Date:2/10/2016)... ... February 10, 2016 , ... As part of its ongoing series of ... Each webinar features a dynamic expert and thoughtful presentation to give attendees a ... facilities. Both events are free to attend, but registration is required. ...
(Date:2/10/2016)... ... February 10, 2016 , ... Emergency rooms provide emergency care to ... this can leave patients with dental emergencies at risk of losing a tooth or ... dental care. , Common dental emergencies include:, , Avulsed ...
(Date:2/10/2016)... ... 10, 2016 , ... Intalere’s 2016 Executive Forum, taking place ... the country’s top healthcare executives to share insights on transformational strategies to drive ... is the provider-centric perspective, experience, expertise and strategy shared by the participants,” said ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... Emmy award winner and inspirational speaker Jan Fox will serve as keynote speaker ... Boldly will provide participants with tools to more effectively communicate with their own ...
Breaking Medicine News(10 mins):